Save up to 30% on Balversa product of USA in non-English packaging.
English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.
Information about Balversa (Erdafitinib)
Balversa (Erdafitinib) is primarily used to treat advanced or metastatic urothelial carcinoma (a type of bladder cancer) that has a specific genetic mutation. It is indicated for patients whose cancer has progressed during or following treatment with platinum-based chemotherapy and who have certain genetic alterations in the FGFR (fibroblast growth factor receptor) genes.
The active ingredient in Balversa is Erdafitinib, a selective inhibitor of the FGFR family of receptor kinases. FGFRs play a crucial role in cancer cell growth and proliferation, and targeting these receptors can help inhibit tumor growth.
Product Highlights
- Advanced or metastatic urothelial carcinoma (bladder cancer) with specific FGFR genetic mutations.
- Use in specific cases of urothelial carcinoma with FGFR genetic mutations.
- Selective inhibitor of FGFR (fibroblast growth factor receptors), which are involved in cancer cell growth and proliferation.
- Regular blood tests and check-ups to monitor side effects and adjust dosage as needed.
Key Ingredient
Key Benefits
- Specifically targets and inhibits FGFRs, which are involved in cancer cell growth in certain types of bladder cancer.
- Can be effective in patients with specific FGFR genetic alterations, especially when other treatments have failed.
- Taken as an oral tablet, which can be more convenient than intravenous treatments.
Directions for Use
- The dosage and treatment regimen will be determined by the prescribing physician based on individual patient factors and tolerance.
- Usually taken once daily, with or without food. It is important to follow the exact dosage and schedule prescribed by your healthcare provider.
- If a dose is missed, take it as soon as possible unless it is almost time for the next dose. Do not double up on doses to make up for a missed one.
Safety Concern
- Common side effects include fatigue, nausea, diarrhea, decreased appetite, and possible liver enzyme elevations. Regular monitoring and blood tests are required.
- May cause serious side effects such as vision changes, liver problems, and increased phosphate levels in the blood, which can lead to complications like mineral and bone disorders.
- Patients will need to have regular check-ups to monitor for these potential side effects.
Avoid Balversa (Erdafitinib) If
- Should not be used during pregnancy or breastfeeding due to potential harm to the fetus or infant.
- If you have a known allergy to Erdafitinib or any other component of the medication, it should be avoided.
- If you have severe liver impairment or certain other significant health conditions, Balversa may not be suitable, and alternatives should be considered.
